Quantitation of Cirtuvivint (SM08502) in Human Plasma by LC–MS/MS
Biomedical Chromatography · 2026-10 · 40 (10)
DOI: 10.1002/bmc.70565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 18.08.2026. Verfasst von Julianne L Holleran und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry, Protein Kinase Inhibitors. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Defense, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
CDC‐like kinases (CLK) and dual‐specificity tyrosine‐regulated kinases (DYRK) are protein kinases involved in various cellular functions, mRNA splicing, and DNA damage repair. CLK/DYRK kinases have been implicated in many disorders such as diabetes, neurodegenerative diseases, and cancer. Cirtuvivint (SM08502) is an orally bioavailable, first‐in‐class pan‐CLK and pan‐DYRK inhibitor that modulates pre‐mRNA splicing and has shown the ability to inhibit cancer cell growth in vitro and reduce tumor burden in vivo. This has led to the administration of cirtuvivint in phase I clinical trials. To quantitate cirtuvivint, we have developed and validated an LC–MS/MS method in human plasma. The assay is simple and robust and consists of a protein precipitation, dilute‐and‐shoot extraction method using 20 μL of plasma, chromatographic separation with a Phenomenex Kinetex C18, and a gradient mobile phase system consisting of 0.1% formic acid in water and acetonitrile. The chromatographic method is followed by mass spectrometric detection with a SCIEX 4500 tandem mass spectrometer. The method has a 5‐min run time and is linear from 5 to 1000 ng/mL. The assay met the criteria outlined by the US Food and Drug Administration guidance for bioanalytical method validation and will support ongoing and future clinical studies defining cirtuvivint pharmacokinetics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
- Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Internal Medicine, Section of Medical Oncology and Hematology, Yale University School of Medicine and Yale Comprehensive Cancer Center, New Haven, Connecticut, USA.
ORCID-Profile: Joshua J Deppas, Michael J Hochman, Maximilian Stahl, Timothy W Synold, Jan H Beumer, Raman Venkataramanan, Robert A Parise
Förderung
- U.S. Department of Defense
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Holleran, J. L., Deppas, J. J., Feng, Y., Hochman, M. J., Chen, E. C., Stahl, M., Gore, S. D., Synold, T. W., Beumer, J. H., Venkataramanan, R., & Parise, R. A. (2026). Quantitation of Cirtuvivint (SM08502) in Human Plasma by LC–MS/MS. Biomedical Chromatography, 40(10). https://doi.org/10.1002/bmc.70565
Vancouver
Holleran JL, Deppas JJ, Feng Y, Hochman MJ, Chen EC, Stahl M, et al. Quantitation of Cirtuvivint (SM08502) in Human Plasma by LC–MS/MS. Biomedical Chromatography. 2026;40(10). doi:10.1002/bmc.70565
BibTeX
@article{Holleran2026,
author = {Holleran, Julianne L and Deppas, Joshua J and Feng, Ye and Hochman, Michael J and Chen, Evan C and Stahl, Maximilian and Gore, Steven D and Synold, Timothy W and Beumer, Jan H and Venkataramanan, Raman and Parise, Robert A},
title = {Quantitation of Cirtuvivint (SM08502) in Human Plasma by LC–MS/MS},
journal = {Biomedical Chromatography},
year = {2026},
volume = {40},
number = {10},
doi = {10.1002/bmc.70565}
}
EUVIMED